ILMN

The stock fell after touching a 52-week high as investors took profits due to valuation concerns and heavy insider sales.

RBC Capital Markets raised its price target to $310 from $230, citing accelerating clinical sales and AI integration.

The stock surged due to S&P 500 index inclusion and a price target upgrade from $225 to $305 by Piper Sandler.

Illumina stock surged following its official readmission to the S&P 500 Index, driving forced buying from passive index funds.

Shares surged due to institutional buying following Illumina's S&P 500 inclusion and a technical breakout above key resistance.

The stock surged following Illumina's official addition to the S&P 500 Index, driving strong passive ETF buying and rebalancing.

Illumina rejoined the S&P 500 index, driving passive buying alongside a strong Q2 earnings beat, raised guidance, and analyst upgrades.

The stock surged due to S&P 500 re-inclusion, major Wall Street analyst upgrades, and strong Q2 earnings momentum.

Illumina surged due to its promotion to the S&P 500 index, analyst upgrades, and strong Q2 earnings momentum with raised guidance.

Illumina stock surged due to institutional buying ahead of its readmission into the S&P 500 Index on September 21, 2026.

Illumina stock surged due to S&P 500 index rejoining news, major analyst upgrades, and technical momentum.